Sensible Medical Innovations, an Israeli startup specializing in solutions for the non-invasive measurement of lung fluid, announced the completion of a $20M funding round
Israeli startup Sensible Medical Innovations, behind the development of a non-invasive monitor for measuring lung fluid, announced the completion of a funding round. While the value of the round was not released by the company, Israeli news site Globes cites unnamed sources having the amount at $20M.
The current funding round was led by Boston Scientific Corporation, together with LongTec Medical Technology and existing investors SCP Vitalife and Genesis Partners.
Helping the medical world
Sensible Medical Innovations’ monitor is capable of measuring the amount of fluid in the lungs of patients using non-invasive technology designed to make the process easier not only for patients but also for doctors. The company’s product is intended for patients with issues of fluid accumulation, which also includes patients recovering from cardiac events, taking diuretics, living with kidney disease and the like.
The solution offered by the company is designed in such as to allow patients and physicians to monitor liquid in lungs more accurately than before factoring the liquid weight and symptoms of the patient. Thanks to this new non-invasive technology, patients can wear the monitor on them and do not need any further surgery to insert measuring devices into their bodies. The result is effective improvement in quality of care while reducing the overall cost associated with hospitalization time, surgery and follow-up care.
Professor Stefan Anker, President of the Heart Failure Association of the European Society of Cardiology and a member of Sensible’s Physician Steering Committee explains how, “Current data provide(s) promising evidence that the device can be used as an effective tool to improve patient care and outcomes in a disease that still has high mortality rates and significant costs to society. This non-invasive technology appears well suited for medical needs in Europe.”
CEO, Amir Ronen, added “We (Sensible Medical Innovations) are humbled and excited to join forces with our new investors whose funding will help bring the company to the next leve. We are proud that our technology has been embraced by leading physicians worldwide who are helping us in our path towards commercialization. A robust and accurate technology for non-invasive fluid monitoring is clearly a dramatic and disruptive capability that could impact the lives of millions.”
Sensible Medical Innovations was founded in 2007 by Amir Ronen, Amir Saroka, Dan Rappaport, Nadav Mizrahi and Shlomi Bergida. Currently the company employs approximately 40 people working at the company’s headquarters located in Kfar Netter. The company now plans to use the current amount of funding to continue to collect data from clinical studies regarding its product’s performance and to help launch it commercially for physicians and patients around the world.
Photo Credit: Shutterstock / Doctor examining radiography